Improving access to Alzheimer's treatment for African American and white patients in Alabama
EQUITY IN ACCESS TO ALZHEIMER'S DISEASE PHARMACOLOGIC TREATMENT FOR AFRICAN AMERICAN AND WHITE PATIENTS IN ALABAMA A MIXED METHODS STUDY TO INFORM RECOMMENDATIONS EquAAL
This study is looking at the challenges that African American and white patients in Alabama encounter when trying to access new Alzheimer's treatments, like lecanemab, and aims to find ways to make these treatments easier and fairer for everyone to get.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10976201 on NIH RePORTER |
What this research studies
This research investigates the barriers that African American and white patients in Alabama face in accessing new Alzheimer's disease treatments, such as lecanemab. It aims to understand the full costs associated with these treatments, including copayments, specialist visits, and travel expenses. By conducting qualitative analyses, the study will explore the availability, accessibility, affordability, and overall perceived value of these new drugs. The goal is to develop recommendations for equitable access to care for older adults affected by Alzheimer's disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American and white patients aged 65 and older who are affected by Alzheimer's disease and reside in Alabama.
Not a fit: Patients outside of Alabama or those not affected by Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved access to effective Alzheimer's treatments for underserved populations, ultimately enhancing patient outcomes.
How similar studies have performed: Previous research has shown that addressing access disparities in healthcare can lead to improved treatment outcomes, suggesting that this approach may be effective.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Pisu, Maria — University of Alabama at Birmingham
- Study coordinator: Pisu, Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.